CompletedInterventionalPhase 2Updated Jan 31, 2014
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines | NCT01189747 | Trialant
CompletedInterventionalPhase 3Updated May 7, 2019
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines
ClinicalTrials.gov ID
NCT01189747
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
446Actual
Last Update Posted
May 7, 2019Actual
Start Date
Oct 1, 2010Actual
Primary Completion Date
Apr 1, 2011Actual
Completion Date
Jul 1, 2011Actual
Brief Summary
This study will evaluate the safety and efficacy of botulinum toxin Type A compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthal Rhytides).
Lateral Canthus Rhytides
Crow's Feet Lines
onabotulinumtoxinA
normal saline
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Moderate to severe Crow's Feet Lines
Have adequate vision without the use of eyeglasses to assess facial wrinkles in a mirror (contact lenses OK)
Exclusion Criteria:
Current or previous botulinum toxin treatment of any serotype
Facial laser or light treatment, microdermabrasion or superficial peels within 3 months
Oral retinoid therapy within 1 year
Prior facial cosmetic surgery (eg, periorbital surgery, facial lift, brow lift, eye lift, or eyebrow surgery)
Diagnosis of myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis